# MARS - Monitored Atherosclerosis Regression Study

> **NCT00116870** · PHASE2,PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 270 (—)

## Conditions studied

- Atherosclerosis
- Coronary Artery Disease

## Interventions

- **DRUG:** lovastatin

## Key facts

- **NCT ID:** NCT00116870
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1985-06
- **Primary completion:** 1992-02
- **Final completion:** 1992-02
- **Target enrollment:** 270 (—)
- **Last updated:** 2009-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116870, "MARS - Monitored Atherosclerosis Regression Study". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00116870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*